Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0557 · 5 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd. |
| 2 | OTHER | MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd. |
| Name | Type | Description |
|---|---|---|
| MK0557 | DRUG | - |
| Comparator: Placebo (unspecified) | DRUG | MK0557 Pbo tablet qd for a 15-wk treatment period |
Inclusion Criteria: * Obese men and nonpregnant women between the ages of 18 and 65 years with a body mass index (height to weight ratio) as required by the study. Exclusion Criteria: * Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)
Top 20 of 35 competitors
MK0557 was studied for the treatment of obesity and for paranoid schizophrenia, specifically cognitive impairment in patients with schizophrenia. It is an investigational small molecule that was developed by Merck & Company, Inc. and tested in four completed clinical trials across these two indications.
MK0557 targets NPY5R, the neuropeptide Y Y5 receptor, and acts as an antagonist. By blocking this receptor, the drug was designed to interfere with neuropeptide Y signaling, a pathway implicated in appetite regulation and body weight control, which is why obesity was a primary focus of its clinical development.
MK0557 was developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the clinical trial program for the compound, including studies in obesity and in cognitive impairment associated with schizophrenia.
MK0557 reached Phase 3 in obesity, with a one-year study in obese patients. All four clinical trials of MK0557 are listed as completed, and no trials are currently active. The compound remains an investigational drug and is not approved for any indication.
MK0557 has been evaluated in four completed trials: NCT00533598 and NCT00533481 in obesity, NCT00482430 in cognitive impairment in schizophrenia, and NCT00092872, a Phase 3 one-year obesity study. Total enrollment across these trials was approximately 2,356 participants.